Generic name: TAFENOQUINE SUCCINATE 150mg
Dosage form: tablet, film coated
Drug class: Antimalarial quinolines
Medically reviewed by Drugs.com. Last updated on Dec 1, 2021.
Tests to be Performed Prior to Treatment with KRINTAFEL
All patients must be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to prescribing KRINTAFEL [see Contraindications (4), Warnings and Precautions (5.1)].
Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with KRINTAFEL [see Use in Specific Populations (8.1, 8.3)].
Recommended Dosage and Administration
The recommended dose of KRINTAFEL in patients aged 16 years and older is a single dose of 300 mg administered as two 150-mg tablets taken together. Coadminister KRINTAFEL on the first or second day of chloroquine therapy for acute P. vivax malaria [see Clinical Studies (14)].
Administer KRINTAFEL with food to increase systemic absorption [see Clinical Pharmacology (12.3)].
Swallow tablets whole. Do not break, crush, or chew the tablets.
In the event of vomiting within 1 hour after dosing, a repeat dose should be given. Re-dosing should not be attempted more than once.
Frequently asked questions
- What is the difference between Arakoda and Krintafel?
- How do you take Arakoda for the prevention of malaria?
- How do you take Krintafel?
More about Krintafel (tafenoquine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antimalarial quinolines
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.